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Background: Studies have reported current hormonal contraceptive use is associated with adverse cardiovascular
outcomes, including high blood pressure. The aim of this study was to determine the association between past
hormonal contraception use and high blood pressure in Australian postmenopausal women.
Methods: Women were recruited from the 45 and Up Study, an observational cross-sectional study, conducted from
February 2006 to December 2009, NSW Australia. All of the variables used in this study were derived from self-reported
data. These women reported being postmenopausal, having an intact uterus, and had given birth to one or more
children. Odds ratios and 99% confidence intervals for the association between past hormonal contraceptive use
and current treatment for high blood pressure, stratified by current age (<58 yrs, 58–66 yrs, and ≥67 yrs) were
estimated using logistic regression, adjusted for income, country of origin, BMI, smoking, alcohol, exercise, family
history of high blood pressure, menopausal hormone therapy use, number of children, whether they breastfed,
and age of menopause.
Results: A total of 34,289 women were included in the study. No association between past hormonal contraception
use and odds of having high blood pressure were seen in any of the age groups (<58 yrs: odds ratio (OR) 1.1, 99%
confidence interval (CI) 0.8 to 1.5, p = 0.36; 58–66 yrs: OR 0.9, 99% CI 0.7 to 1.1, p = 0.11; and ≥67 yrs: OR 0.9, 99% CI 0.8
to 1.0. p = 0.06). In women with a history of hormonal contraception use, no association between duration of hormonal
contraception use and high blood pressure was observed.
Conclusions: Past hormonal contraception use and duration of use is not associated with high blood pressure in
postmenopausal women.
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Hormonal contraceptives are the most commonly used
method of birth control worldwide. Since their intro-
duction in the 1960s, adverse cardiovascular outcomes,
including increased risk of myocardial infarction [1],
stroke [1,2], venous thrombosis [3] and high blood
pressure [4-6] have been reported. These studies have
predominantly looked at current hormonal contracep-
tion use in younger women.
Hypertension (high blood pressure) is a leading cause
of morbidity and mortality in postmenopausal women.
Endogenous estrogens are thought to protect women
against vascular disease and atherosclerosis [7], while* Correspondence: j.lind@uws.edu.au
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unless otherwise stated.exogenous estrogens have been associated with in-
creased risk of stroke and high blood pressure [8,9]. The
Nurse’s Health Study investigated the effect of long term
hormonal contraception use on cardiovascular disease
mortality, and found no association between increasing
duration of past hormonal contraceptive use and total
mortality related to cardiovascular disease [10].
The present study investigated the relationship be-
tween past hormonal contraception use and likelihood
of high blood pressure in Australian postmenopausal
women. The aim of this study was to determine the as-
sociation between past hormonal contraception use and
the likelihood of having high blood pressure.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data was obtained from women who were recruited
from the 45 and Up Study. The methods for the 45 and
Up Study have been described elsewhere [11]. Briefly,
the 45 and Up Study is a large scale cohort study of
healthy ageing that involves men and women aged
45 years and over from the general population of New
South Wales, Australia. Individuals were sampled from
the Medicare Australia database. Study recruitment
started in January 2006 and was completed in April
2009. The 45 and Up Study received ethics approvalNever used OC
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Figure 1 Participants included in the study.from the University of NSW Human Ethics Committee
(HREC 10186) and the current study was approved by
the University of Western Sydney Human Research
Ethics Committee (H8561).
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contraception? (in years)” and “If Yes, how old were you
when you LAST used hormonal contraceptives?”. Women
were also asked “Which type of pill or other hormonal
contraceptive did you use MOST RECENTLY; combined
pill; progesterone only; Depo Provera; contraceptive im-
plant; or do not know?”. Examples of common brands
were given with each type. Progesterone only, Depo Pro-
vera and contraceptive implant were combined as the pro-
gestin group. Women whose current age was greater than
the age they reported last using hormonal contraception
were classified as past users. Hormonal contraception use
was analysed as a dichotomous variable (past use/never).
Duration of use in years was analysed as a categorical vari-
able (never, <5 years, 5 to 10 years, and >10 years).
Women with missing or invalid data for these variables
were excluded. Women were identified as having high blood
pressure if they answered “Yes” to the question “In the last
month have you been treated for: high blood pressure”.
Odds ratios and 99% confidence intervals were esti-
mated using logistic regression. Both crude and adjusted
odds ratios were calculated and descriptions refer to ad-
justed odds ratios unless otherwise specified. Odds ratios
were adjusted for demographic and lifestyle factors that
were significantly associated with treatment for high
blood pressure in univariate analysis. Namely, income,
country of origin, BMI, smoking, alcohol, exercise, fam-
ily history of high blood pressure, menopausal hormone
therapy use, number of children, whether they breastfed,
and age of menopause, with additional categories for
missing values (Table 1). For ‘Country of birth’, partici-
pants were classified according to whether they had been
born in Australia or born in a country other than
Australia. Physical activity levels were assessed using
questions from the Active Australia Survey Vigorous ac-
tivity as previously described [8]. Smoking was classified
as current, past or never, according to the questions
“Have you ever been a regular smoker?” and if yes, “Are
you a regular smoker now?”. Consumption of alcohol
was classified into the groups shown in Table 1 based on
the question “About how many alcoholic drinks do you
have each week?”.
Tests for interactions between covariates and past hor-
monal contraception use, with odds for high blood pres-
sure were performed. A significant interaction between
age and past hormonal contraception use with having
high blood pressure was observed (p < 0.001). As a re-
sult, women were stratified according to age and divided
into tertiles (<58 yrs, 58–66 yrs, and ≥67 yrs). Odds ra-
tios were calculated for each age group. All statistical
tests were two-sided, using a significance level of p <
0.01 to partially account for multiple testing issues [12].
Conclusions were drawn based on both significance and
the effect size.Results
A total of 34,289 women were included in the study
(Figure 1) of which 75% reported past hormonal contra-
ceptive use and 21% reported current treatment for high
blood pressure. These women were postmenopausal, re-
ported having an intact uterus, had given birth, and had
not had high blood pressure while pregnant. Past hor-
monal contraception use was lowest in women who
were born prior to 1930 and highest in women who
were born during the 1950s, with a large percentage (85
to 88%) of women that were born between 1940 and
1960 reporting previous hormonal contraception use.
Women who had previously used hormonal contracep-
tives were significantly younger than women who had
never used hormonal contraceptives, 61.0 years com-
pared to 71.4 years, respectively (β -10.4; CI 99% -10.7
to −10.1; p < 0.001).
Demographic and lifestyle characteristics of past users
compared to women who have never used hormonal
contraceptives are outlined in Table 1. Women who re-
ported being born in Australia, had a higher income,
were physically active, were current smokers, reported
drinking alcohol, had 2 or 3 children, and had a history
of menopausal hormone therapy use were more likely to
have used hormonal contraceptives, compared to women
who were not born in Australia, had a lower incomes,
were non-smokers and non-drinkers, had not used
menopausal hormone therapy, and who had only one
child, respectively.
In all age groups no association between previous hor-
monal contraceptive use and high blood pressure was
observed (Table 2). Similarly, duration of hormonal
contraception use was not associated with odds for high
blood pressure in any age group, when compared to
never users. Within women who reported hormonal
contraception use, there was no difference in odds for
high blood pressure between those that had used hor-
monal contraception for less than 5 years and those that
had used it for 5 to 10 years, or greater than 10 years
(Table 3).
Of the women who had used hormonal contraception,
the combined pill was the most common type of hormo-
nal contraception used by women in all age groups, with
over half of women reported having last used the com-
bined pill compared to the less than 15% of women who
reported last using a progestin based formulation.
Discussion
This study found past hormonal contraception use was
not associated with subsequent high blood pressure in a
cohort of postmenopausal Australian women. Addition-
ally, duration of hormonal contraception used was not
associated with odds of having high blood pressure.
Women who were born prior to 1930 were significantly
Table 1 Socio-demographic factors and health risk factors associated with hormonal contraception use
Characteristics n (% column) % HC Odds ratio† (99% CI)
Country of origin Australia 25,664 (75) 79 1.0
Other 8,348 (24) 64 0.5 (0.4 to 0.5)
Income <$30 K 10,294 (30) 64 1.0
$30 K – $70 K 8687 (25) 83 2.2 (2.1 to 2.4)
$70 K+ 7,037 (21) 89 3.7 (3.4 to 4.0)
Did not disclose 8,271 (24) 69 1.2 (1.1 to 1.3)
Body Mass Index (BMI) <25 15,561 (45) 75 1.0
25 to 29 10,410 (30) 76 1.1 (1.1 to 1.2)
+30 5,731 (17) 77 1.4 (1.3 to 1.5)
Family History HBP No 16,994 (50) 71 1.0
Yes 17,295 (50) 79 1.3 (1.3 to 1.4)
Smoking status Never 22,626 (66) 72 1.0
Past 9,483 (28) 82 1.5 (1.4 to 1.6)
Current 2,040 (6) 81 1.9 (1.7 to 2.2)
Alcohol (drinks/week) 0 13,137 (38) 65 1.0
1-5 9,276 (27) 81 1.7 (1.6 to 1.8)
6-10 6,889 (20) 82 1.7 (1.6 to 1.9)
11+ 4,335 (13) 86 1.9 (1.7 to 2.1)
Physical activity Insufficient 10,071 (29) 66 1.0
Sufficient 24,218 (71) 79 1.6 (1.5 to 1.7)
MHT use No 21,531 (63) 42 1.0
Yes 12,422 (36) 85 2.3 (2.2 to 2.4)
Number of children 1 3,580 (10) 71 1.0
2 13,772 (40) 82 1.5 (1.4 to 1.7)
3 10,184 (30) 78 1.3 (1.1 to 1.4)
4+ 6,753 (20) 63 0.7 (0.6 to 0.8)
Breastfed No 3,986 (12) 72 1.0
Yes 29,889 (87) 76 1.1 (1.0 to 1.1)
Age at menopause (years) mean ± SD 49.9 ± 4.5 −0.01(−0.01 to −0.001)*
HC = Hormonal Contraceptive; OR = Odds Ratio; CI = Confidence Interval. % HC is the percentage of women who responded yes to having ever used hormonal
contraception. Percentages do not consistently total to 100% due to missing values. †Adjusted for age, country of origin, income level, body mass index, family
history of high blood pressure, smoking status, alcohol consumption, physical activity, menopausal hormone therapy (MHT) use, number of children, whether they
breastfed, age at menopause. *Linear variable, therefore beta value and 99% CI reported.
Table 2 The odds for having high blood pressure in postmenopausal women who had previously used hormonal
contraceptives compared with women who have never used hormonal contraceptives, stratified by current age
Current age HC use n % HBP Unadjusted OR (99% CI) Unadjusted P value Adjusted† OR (99% CI) Adjusted P value
<58 yrs Never 1411 8.9 1.0 1.0
Past use 10647 10.6 1.2 (0.9 to 1.6) 0.05 1.1 (0.8 to 1.5) 0.36
58 to 66 yrs Never 1586 20.7 1.0 1.0
Past use 9213 19.6 0.9 (0.8 to 1.1) 0.29 0.9 (0.7 to 1.1) 0.11
≥67 yrs Never 5512 33.2 1.0 1.0
Past use 5920 33.4 1.0 (0.9 to 1.1) 0.86 0.9 (0.8 to 1.0) 0.06
HC = Hormonal Contraceptive; HBP = High Blood Pressure; OR = Odds Ratio; CI = Confidence Interval. †Adjusted for income, country of origin, BMI, smoking,
alcohol, exercise, family history of high blood pressure, menopausal hormone therapy use, number of children, whether they breastfed, and age of menopause.
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Table 3 The odds of having high blood pressure
depending on duration of hormonal contraception use
compared to never use, stratified by current age
Current age HC use n % HBP OR (99% CI)† P value
<58 years Never 1411 8.9 1.0
<5 years 2677 9.7 1.0 (0.7 to 1.4) 0.99
5 to 10 years 3903 10.8 1.2 (0.9 to 1.6) 0.24
>10 years 4067 11.0 1.2 (0.9 to 1.6) 0.22
58 to 66 years Never 1586 20.7 1.0
<5 years 2930 18.7 0.9 (0.7 to 1.1) 0.05
5 to 10 years 3636 19.7 0.9 (0.7 to 1.1) 0.17
>10 years 2647 20.4 0.9 (0.8 to 1.2) 0.42
≥67 years Never 5512 33.2 1.0
<5 years 1817 33.9 1.0 (0.8 to 1.1) 0.38
5 to 10 years 2169 33.7 0.9 (0.8 to 1.1) 0.23
>10 years 1934 32.5 0.9 (0.8 to 1.0) 0.04
HBP = High Blood Pressure; OR = Odds Ratio; CI = Confidence Interval.
†Adjusted for income, country of origin, BMI, smoking, alcohol, exercise, family
history of high blood pressure, menopausal hormone therapy use, number of
children, whether they breastfed, and age of menopause.
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hormonal contraception was not available in Australia
until 1961 and was not widely accessible until the early
1970s. By this time, women born prior to 1930 most
likely did not require contraception.
Studies have repeatedly reported increases in blood
pressure with current hormonal contraception use
[4,6,13-15]. These studies also demonstrated that this
effect quickly diminishes once hormonal contraception
is stopped [6,13,15,16]. Very few studies have focused
on past hormonal contraception use and risk of subse-
quent high blood pressure. The Nurse’s Health Study
(NHS) reported past hormonal contraception use, and
duration of use, did not increase a woman’s risk of car-
diovascular disease, stroke, or coronary artery disease
[10,17,18]. A secondary study (NHS II) study found
past users had a slight but not significant increase in
risk for hypertension [19].
The women included in this study represent a cohort
of women who were exposed to early generations of hor-
monal contraception, and the results of this study likely
reflect associations with higher dose formulations. The
later generations of hormonal contraceptives contain
lower doses of estrogen and progestin, as well as newer
combinations of the hormones [20]. Recent studies using
lower dosage contraceptives have shown a reduction in
the size of the effect on risk of cardiovascular disease
[21]. As formulations and delivery methods change, the
effect of long term hormonal contraception use on risk
of subsequent high blood pressure may change and
would be of interest to both the women receiving treat-
ment and their prescribing clinician.A limitation of the study was that it analysed cross-
sectional observational data, and as a result, the cause
could not be established. The study also relied on self-
reported data which is prone to potential recall bias, and
may lead to under-reporting or over-reporting of diagno-
sis of high blood pressure, menopause status, and dur-
ation of hormonal contraception use. Furthermore
factors that are known to influence the incidence of high
blood pressure, including type and dosage of hormonal
contraception could not be determined. The hormone
type that was most recently used was reported, however
it is probable that in the time preceding data collection,
women may have used different hormonal contracep-
tives with varying combinations of estrogen and proges-
tin dosage. Additionally, women who have high blood
pressure at the time of requiring contraception are often
advised against hormonal contraception use, as high
blood pressure is a contraindication for hormonal
contraceptive use. In an attempt to overcome this, we
excluded women who had been diagnosed with high
blood pressure prior to 30 years of age as it is unlikely
the cause of high blood pressure in these women is a re-
sult of exposure to hormonal contraception.Conclusions
This study found past hormonal contraceptive use, and
duration of use, was not associated with high blood
pressure in Australian postmenopausal women.Ethics approval
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